Event information
4 March 2026
Zoom Webinar
This event will run from 10:30 to 12:00 (ET).
For the latest in our Risk of Living Longer Series of webinars, it is a great pleasure to host an extensive panel of experts to discuss the potential longevity impact of anti-obesity medications.
In previous sessions in the series we have taken a deep dive into the metabolic health crisis affecting populations around the world. But with many people struggling with lifestyle changes to improve weight and metabolic health, the potential for anti-obesity medications (including GLP-1 and GIP receptor agonists) to kickstart a new era of longer lives has become a key area of focus. Over the last 6 months, a range of longevity stakeholders have released research papers that quantify the impact of different scenarios for engagement with these medications. In this webinar, we host a panel from five of these organisations to explore their different approaches, compare their results and discuss potential future developments for anti-obesity medication.
Join hosts Uli and Erik for a dynamic session featuring five distinguished experts:
- Daniel Meier (Head Life & Health Risk Modelling, Swiss Re)
- Richard Russell (VP of Biometric Research, RGA)
- Tristan Walsh (Staff Data Scientist, Munich Re)
- Ashley Campbell (Director of Actuarial, Crystallise)
- Mia Marcellus (Longevity Modeler, Club Vita)
Key Questions Answered:
- Why is everyone talking about anti-obesity medication?
- How much could emerging treatments impact future mortality rates?
- How are reinsurers and longevity experts measuring the potential impact?
- What are the key areas to monitor for emerging information on the impact of anti-obesity medications?
Speakers
The Risk of Living Longer Series, S05 E01
The GLP-1 effect: The potential impact of anti-obesity medication on longevity